$BIIB Recent Headlines Biogen Idec investors focus on

New Post Public Reply Private Reply Replies (0) Message Board

Jan 31, 2014 at 3:26 PM

$BIIB Recent Headlines

Biogen Idec investors focus on positive, ignore outlook for 2014 2:02 p.m. Jan. 29, 2014 - blogs.marketwatch.com
Biogen profit jumps on MS treatment revenue 7:09 a.m. Jan. 29, 2014 - MarketWatch.com
Stock investors trash market darlings, face Apple, Fed 8:00 a.m. Jan. 26, 2014 - Wallace Witkowski
The market puts a few feathers in its cap 1:58 p.m. Jan. 23, 2014 - The Trading Deck
Speculators turn the heat up to ‘soft boil’ 3:54 p.m. Jan. 16, 2014 - The Trading Deck
GameStop tumbles 20%; Tesla surges on strong sales 4:22 p.m. Jan. 14, 2014 - Ben Eisen
Beam up on Suntory deal; Elliott report lifts Juniper 4:17 p.m. Jan. 13, 2014 - Saumya Vaishampayan
Biogen, Sangamo partner on hemoglobin therapies 9:38 a.m. Jan. 9, 2014 - MarketWatch.com
Earnings boost Micron, drag on Container Store 4:24 p.m. Jan. 8, 2014 - Ben Eisen
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Charting a bullish year-end backdrop 12:28 p.m. Dec. 17, 2013 - Michael Ashbaugh
Charting a bullish year-end backdrop 12:03 p.m. Dec. 17, 2013 - Michael Ashbaugh
Get your portfolio to turn the corner 2:32 p.m. Dec. 10, 2013 - The Trading Deck
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Growth stock players should reduce expectations 1:18 p.m. Nov. 26, 2013 - The Trading Deck
DaVita, Fresenius gain; energy firms slip 4:55 p.m. Nov. 25, 2013 - Ben Eisen
Stocks gain for 7th week; S&P ends above 1,800 4:24 p.m. Nov. 22, 2013 - Polya Lesova
Biogen Idec jumps; Intel, Ross Stores slide 4:23 p.m. Nov. 22, 2013 - Ben Eisen
Biogen surges 13%, best on S&P 500 9:33 a.m. Nov. 22, 2013 - Laura Mandaro
The Four Horsemen send a message 12:46 p.m. Nov. 13, 2013 - The Trading Deck

Biotech Sector Performance January 2014 Strong, but What's Ailing Celgene? 2:12 p.m. Today - TheStreet.com
Zacks Rank #1 Additions for Friday - Tale of the Tape 9:30 a.m. Today - Zacks.com
Facebook Tops 5 Leaders With Rising Profit Estimates 8:00 a.m. Today - Investors Business Daily
Jefferies Says Buy Any Pullback on Top Focus Stocks for Big Gains 7:22 a.m. Today - 247WallSt.com
Biogen Idec Is a Buy Idea 12:09 a.m. Today - Barrons.com
Celgene -2.2% after earnings, NEJM report, while other big biotechs surge 2:44 p.m. Jan. 30, 2014 - Seeking Alpha
Biogen Idec Inc. (BIIB): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Jan. 30, 2014 - Zacks.com
FDA Nod for New Formulation of Teva's Copaxone - Analyst Blog 5:10 p.m. Jan. 29, 2014 - Zacks.com
Biogen's Report Sends Stock Up; Other Biotechs Follow 5:01 p.m. Jan. 29, 2014 - Investors Business Daily
Will Affymetrix (AFFX) Surprise This Earnings Season? - Analyst Blog 4:30 p.m. Jan. 29, 2014 - Zacks.com
Biogen Beats, Tecfidera Continues to Shine - Analyst Blog 1:32 p.m. Jan. 29, 2014 - Zacks.com
Biogen Idec Management Discusses Q4 2013 Results - Earnings Call Transcript 12:50 p.m. Jan. 29, 2014 - Seeking Alpha
Why Caution Is Prevailing in Biotechs Into and After Earnings 11:29 a.m. Jan. 29, 2014 - 247WallSt.com
New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN) 10:44 a.m. Jan. 29, 2014 - benzinga.com
Biogen MS Drug Tecfidera Outperforms; Outlook Light 10:41 a.m. Jan. 29, 2014 - Investors Business Daily
Top Trending Tickers On StockTwits For January 29 8:51 a.m. Jan. 29, 2014 - benzinga.com
An Option On Adoption Of A New Multiple Sclerosis Treatment 8:51 a.m. Jan. 29, 2014 - Seeking Alpha
Biogen profit powers higher on strong sales for MS treatment 8:14 a.m. Jan. 29, 2014 - Seeking Alpha
The Best of the Best Picks of the Credit Suisse Top 50 Stocks 8:09 a.m. Jan. 29, 2014 - 247WallSt.com
Facebook, Biogen, Sands Among Top Big Caps Reporting 7:02 a.m. Jan. 29, 2014 - Investors Business Daily

Biogen Idec Foundation Awards Museum of Science $2.5 Million to Support Hall of Human Life 8:30 a.m. Jan. 30, 2014 - BusinessWire - BZX
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia 1:00 a.m. Jan. 30, 2014 - BusinessWire - BZX
Biogen Idec 2013 Total Revenues Increase 26 Percent to $6.9 Billion 6:30 a.m. Jan. 29, 2014 - BusinessWire - BZX
RBCC Develops Innovations in White-Hot 3D Bioprinting Sector 4:00 a.m. Jan. 27, 2014 - BusinessWire - BZX
RXI Pharmaceuticals Could Benefit from Biotech Industry Dynamics 10:06 a.m. Jan. 24, 2014 - ACCESSWIRE
Critical Alerts For General Electric, SodaStream, Biogen Idec, Linn Energy, and Allscripts Released By InvestorsObserver 9:31 a.m. Jan. 24, 2014 - PR Newswire - PRF
RBCC Moves to the Front Lines of the 3D Bioprinting Revolution 5:00 a.m. Jan. 20, 2014 - BusinessWire - BZX
RBCC Prepares Big Push Into Booming 3D Bioprinting Market 5:00 a.m. Jan. 16, 2014 - BusinessWire - BZX
Biogen Idec to Report Fourth Quarter and Year-End 2013 Financial Results on January 29, 2014 4:01 p.m. Jan. 15, 2014 - BusinessWire - BZX
RBCC Partner Therakine Presents Novel Drug Delivery Technology at Biotech Showcase 5:00 a.m. Jan. 15, 2014 - BusinessWire - BZX
Biogen Idec Announces Availability of FAMPYRA® in Ireland to Treat Walking Impairment in Adults with Multiple Sclerosis 4:00 a.m. Jan. 15, 2014 - BusinessWire - BZX
Leading Life Sciences CEOs Honor Johnson & Johnson Chief Scientific Officer Paul Stoffels with Lifetime Achievement Award at Annual East/West CEO Conference 9:49 a.m. Jan. 14, 2014 - BusinessWire - BZX
ShangPharma Appoints Pharmaceutical Executive Dr. Mitchell Reff Chief Biologics Officer 9:10 a.m. Jan. 13, 2014 - PR Newswire - PRF
RBCC Partner n3D Commercializes New 3D Bioprinting Technology 5:53 a.m. Jan. 13, 2014 - BusinessWire - BZX
Sangamo BioSciences Announces Conference Call And Webcast To Discuss Global Collaboration with Biogen Idec to Develop Treatments for Hemoglobinopathies 7:10 a.m. Jan. 9, 2014 - PR Newswire
Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies 7:00 a.m. Jan. 9, 2014 - PR Newswire
Sunesis Pharmaceuticals Expands Hematology Franchise With Global Licenses to Two Kinase Inhibitor Programs 6:59 a.m. Jan. 9, 2014 - GlobeNewswire
Biogen Idec to Present at the 32nd Annual J.P. Morgan Healthcare Conference 5:29 p.m. Jan. 7, 2014 - BusinessWire
Galectin Therapeutics Receives Patent for Combination Treatment for Liver Fibrosis 12:17 p.m. Jan. 7, 2014 - ACCESSWIRE
Stock Price Movement, Financial Reports Schedules, Conference Participation, Leadership Changes, and Donation - Research Report on Biogen Idec, Forest, PerkinElmer, Techne, and USANA 8:00 a.m. Jan. 7, 2014 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SPECS Framework: Rethinking Career Growth Strategies

An Evolving Workplace Demands Evolving Strategies Look, careers ain't what they used to be—and they shouldn't be. Today’s world is flipping the script on how we work, and Dr. Brandi R. Muñoz is rewriting the book on career development with her SPECS framework. The guy clinging to his outdated Rolodex for advice isn't gonna cut it anymore. "Who Are Your SPECS?...

Bird-X Welcomes Doolittle to Elevate Sales Strategy

Change in Flight: Bird-X Eyes Strategic Growth Well, here's one that might spread its wings wide. Emanuel Doolittle has joined Bird-X, Inc. as Director of Sales and Business Development. Now, let's not beat around the bush — Bird-X isn't a name you'd see thrown around daily stock talks, but it's stirring up interest in the pest control sector without question. Why...

Goodal Skincare Capitalizes on K-Beauty Craze at Costco

A Venture into American Retail Goodal, the darling of Korea's skincare scene, is staking its claim at Costco. This is no small feat, my friends. We're talkin' about a brand that's carved out a sweet niche with its Green Tangerine line. Now it's hitching its wagon to one of America's retail behemoths, known for its unique knack in beauty products. From Olive Young to...

DUPR Teams Up with InBody to Elevate Pickleball Fitness

Well, here's a twist in the pickleball world—DUPR and InBody have struck a deal to bring top-notch body composition tech to the ever-expanding universe of pickleballers. They're merging power players from two different worlds to tap into your performance on the court and your wellness off it. Maybe I'm just jaded from too many marketing pitches, but this one could...

PG&E's $2B Delay: A Blame Game or Real Crisis?

Just when you think the circus of energy utilities couldn't get any more outlandish, PG&E grabs the spotlight once more. Picture this: they've got the megaphone out, threatening to put the brakes on $2 billion in crucial infrastructure investments. Twenty-five thousand customers left hanging, just waiting for their lights to come on. As if that's not enough, PG&E is also...

Telemed Sites Need Solid Payment Systems with AI

Brace for Impact: Payment Processors in Telehealth A new era is brewing in telehealth, with AI coding tools making website creation a breeze for healthcare folks. But here's the kicker: accepting credit cards is not as easy as setting up a snazzy booking page. Take it from Organic Payment Gateways in good ol' Scarborough, Maine, who've decided to toss their hat into this...

Luxury Vinyl Tiles Market Set for Steady Growth to 2031

Luxury Vinyl Tiles: A Market on the Rise Well, folks, the flooring game is picking up steam, and luxury vinyl tiles (LVT) are in the spotlight. With consumers and businesses all looking for something durable yet easy on the eyes and wallet, LVT is answering the call. MarketsandMarkets™ reports that this sector is expected to balloon from USD 18.22 billion in 2026 to USD...

Bright Minds in Hot Water: Investigation Shakes Investors

FDA Throws Wrench Into Bright Minds' Plans This ain't the first time a biotech company's dream has hit the skids, but Bright Minds Biosciences (NASDAQ:DRUG) found themselves in the meat grinder when the FDA threw their epilepsy trial plans under the bus. The partial clinical hold wasn't a gentle slap on the wrist, but a gut punch driven by mouse toxicity findings and...

ESAC Redefines Entertainment Centers, Eyes 2027 Trends

A New Era for Family Entertainment Centers Forget the traditional FEC with its solitary rides; the future's all about constructing social destinations that blend immersive storytelling and hybrid offerings. Elephant Sculpture Art Co., Ltd. (ESAC) is at the forefront, drawing from their Shanghai WUNPARK project to reimagine the design of these amusement hubs. Set to engage...

AMETEK Surpasses Q3 2026 Expectations, Raises Outlook

A Banner Quarter for AMETEK Holy smokes, AMETEK has thrown down some numbers for the third quarter of 2026 that would make any seasoned trader sit up and take notice. We’re talking record-breaking across the board: $2.22 billion in sales, marking a whopping 17% increase over last year. Now, that's not just growth—that's rocket fuel. Earnings per share rocketed up with...